927P - Proposal of improved prognostic index for patients with extranodal natural killer/T cell lymphoma treated with non-anthracycline based treatment

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Lymphomas
Presenter Yewon Kang
Citation Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375
Authors Y. Kang1, S. Seo2, J.Y. Hong2, D.H. Yoon2, S. Kim2, J.S. Park2, J. Huh3, S. Lee4, J. Ryu5, C. Suh2
  • 1Department Of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 2Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 3Pathology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 4Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 5Department Of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR

Abstract

Background

Although serum beta-2 microglobulin (B2M) has been suggested as a potential prognostic predictor for patients with extranodal natural killer/T cell lymphoma (ENKTL), there are no prognostic models using B2M. We aimed to investigate the prognostic role of B2M by incorporating B2M into the most recently prognostic models, Prognostic Index of Natural Killer Lymphoma (PINK) and PINK-E (Epstein- Barr virus).

Methods

Between January 2005 to December 2014, 141 patients with ENKTL were identified in the database of the Asan Medical Center, Lymphoma Registry. Among them, 108 patients were treated with non-anthracycline based treatment.

Results

Median B2M value was 2.45 mg/L (range, 1.0-22.0) and baseline B2M was elevated in patients (45.4%). With median follow-up duration of 32.1 months (range, 0.3-131.0), and median overall survival (OS) was not reached. In univariate analysis, elevated B2M level was significantly associated with poorer OS (HR = 3.66; 95% CI: 1.96-6.82; p 

Conclusions

For ENKTL patients treated with non-anthracycline based therapy, we suggest a new prognostic index, consisting of age, stage, distant node involvement, non-nasal type disease and serum B2M, which could be good for discriminating poor risk groups and convenient to apply real practice.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.